Navigation Links
Avanafil Data Presented at the European Society of Sexual Medicine Meeting
Date:12/5/2011

ven PDE isozymes, in comparison with sildenafil, tadalafil and vardenafil. Dr. Wang concluded that, in-vitro, avanafil strongly inhibited PDE5 while demonstrating the highest aggregate selectivity in its class against all other PDE isozymes. 

Lastly, Mark Allison, MD, Certified Physician Investigator from Celerion in Tempe, Arizona presented a poster entitled:

Pharmacokinetics of Avanafil, a Novel, Rapidly Absorbed, Selective PDE5 Inhibitor for the Treatment of Mild to Severe Erectile Dysfunction

In his presentation, Dr. Allison summarized the PK results from several avanafil phase 1 studies which indicated rapid absorption (tmax 30-45 min), short plasma half-life (3-5 hours) and lack of accumulation following multiple dosing.

About AvanafilAvanafil is an investigational oral drug being developed for the treatment of erectile dysfunction.  Avanafil is a highly selective phosphodiesterase type 5 (PDE5) inhibitor licensed from Mitsubishi Tanabe Pharma Corporation. VIVUS owns worldwide development and commercial rights to avanafil for the treatment of sexual dysfunction, with the exception of certain Asian Pacific Rim countries.

About VIVUS VIVUS is a biopharmaceutical company developing therapies to address obesity, sleep apnea, diabetes and male sexual health.  The company's lead investigational product in clinical development, Qnexa, has completed phase 3 clinical trials for the treatment of obesity and is currently being considered for approval by US and EU regulators.  VIVUS received a Complete Response Letter, or CRL, to the initial Qnexa NDA on October 28, 2010.  We resubmitted the Qnexa NDA in October 2011, with an FDA action date of April 17, 2012.  Qnexa is also in phase 2 clinical development for the treatment of type 2 diabetes and obstructive sleep apnea.  In the area of sexual health, VIVUS has submitted an NDA for avanafil, a PDE5 inhibitor being s
'/>"/>

SOURCE VIVUS, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Avanafil Data to be Presented at the Sexual Medicine Society of North America Meeting
2. Positive Results From Avanafil Phase 3 Study in Diabetics Presented at the 47th EASD Annual Meeting
3. VIVUS Announces FDA Acceptance of Avanafil New Drug Application for Treatment of Erectile Dysfunction
4. Positive Results From Avanafil Post-Prostatectomy Study Featured at Cancer Survivorship Meeting
5. Positive Results from Long-Term Phase 3 Study of Avanafil Featured at American Urological Association Annual Meeting
6. VIVUS to Host Conference Call and Webcast Discussion of Avanafil Phase 3 Results
7. VIVUS Initiates Open Label Safety Study of Avanafil for Erectile Dysfunction
8. New Data Demonstrating the Impact of Opioid-Related Adverse Events on Total Hospital Cost Presented at American Society of Health-System Pharmacists Meeting
9. New Data on Vimpat® (lacosamide) C-V to Be Presented at the 65th Annual Meeting of the American Epilepsy Society
10. Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium
11. XEOMIN® (incobotulinumtoxinA) Data to be Presented at the 72nd Annual Assembly of the American Academy of Physical Medicine and Rehabilitation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... , July 24, 2014  Perrigo Company (NYSE: ... has received an AB therapeutic equivalent rating from the ... approved New Drug Application (NDA) for testosterone gel 1.0%. ... to [AbbVie,s] AndroGel 1% and can be substituted with ... clinical effect and safety profile as AndroGel 1% when ...
(Date:7/24/2014)... KIRKLAND, Wash. , July 24, 2014 ... exhibiting at the 2014 National Association of State Veterans ... Carolina . The goal of the NASVH is ... receives the benefits, services, long term health care and ... sacrifice. With the InSite® Remote Dispensing ...
(Date:7/24/2014)... , July 24, 2014  Lazarus Effect, a ... novel interventional devices to facilitate removal of blood ... and Trademark Office has issued a new patent ... the company,s Lazarus Cover TM and ReCover ... ReCover is a single-component stent-retriever (stentriever) with an ...
Breaking Medicine Technology:Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 2Perrigo Confirms AB Therapeutic Equivalent Rating From The FDA For Its Testosterone Gel 1.0% 3Talyst Exhibits at the National Association of State Veterans Homes Summer Conference 2Lazarus Effect Receives Notice of Allowance for New US Patent Covering Core Protection Technology 2
... Healthcare, a world-leading developer, manufacturer and marketer of innovative ... that in connection with a refinancing of its debt ... in combination with new senior secured credit facilities, it ... Senior Notes. The offering of the new notes will ...
... YORK, Dec. 5, 2010 Pfizer Inc. (NYSE: ... Directors has elected Ian C. Read, 57, currently head ... Executive Officer and Director. Mr. Read succeeds Jeffrey B. ... (Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO) The Board,s Lead Independent ...
Cached Medicine Technology:ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 2ConvaTec Healthcare Announces Senior Secured Notes Offering & Senior Notes Offering 3Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 2Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 3Pfizer Board of Directors Names Ian C. Read President and Chief Executive Officer 4
(Date:7/24/2014)... Voted one of the most reliable online dress suppliers ... providing its new and old customers with the latest ... announced its new collection of high end wedding dresses. ... to the latest fashion trends. Additionally, they are now ... As a matter of fact, high end special occasion ...
(Date:7/24/2014)... 2014 The federal judge overseeing ... in the U.S. District Court, District of Massachusetts, ... medical information covered by the federal Health Insurance ... 16th Order, U.S. District Judge Douglas P. Woodlock ... Care the right to receive HIPAA- protected information. ...
(Date:7/24/2014)... 24, 2014 CarePoint Health is ... hematology and oncology, Dr. Hitendra Upadhyaya, has joined ... welcomes Dr. Upadhyaya to the community. Hundreds of ... Medical Group, a comprehensive network of top doctors ... range of specialties. This latest acquisition represents CarePoint ...
(Date:7/24/2014)... treatment of overweight and obese preschoolers works better when ... only the child is targeted, according to research published ... the University at Buffalo and Women and Children,s Hospital ... or obese and had one parent who participated in ... to body mass index (BMI) measurements, calculated based on ...
(Date:7/24/2014)... between two or more equally positive outcomes experience ... with activity in different regions of the brain, ... associate research scholar at the Princeton Neuroscience Institute ... 42 people rated the desirability of more than ... looked at images of paired products with different ...
Breaking Medicine News(10 mins):Health News:BellasDress Helps Brides Get High End Wedding Dresses for Their Romantic Weddings 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 2Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 3Health News:GranuFlo Lawsuits Move Forward in Federal Court, With Issuance of Protective Order for HIPAA Information, Bernstein Liebhard LLP Reports 4Health News:Dr. Upadhyaya Joins CarePoint Health Medical Group 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 2Health News:Overweight and obese preschoolers lose more weight when parent is also treated 3Health News:Brain's dynamic duel underlies win-win choices 2Health News:Brain's dynamic duel underlies win-win choices 3
... ... since 1998, has now processed 1.5 million orders. The website provides lifestyle medications such as ... that is reviewed by a U.S.-licensed doctor. Visitors do not need to have a prescription ... ...
... ... Law & Technology,s information privacy programs and senior fellow to the Samuelson Law, Technology & ... Ad Ops Forum taking place in San Francisco on June 17. , ... (PRWEB) May 18, 2010 -- Chris Jay Hoofnagle, ...
... , ... consultancy providing unique IT solutions for the healthcare industry, announces a new whitepaper on the ... ... -- Arcadia Solutions , a national consultancy providing unique IT solutions for the healthcare ...
... ... on the ten distinct warning signs that foretell violence and the appropriate responses. “Workplace ... approaching the subject directly and honestly. , ... (PRWEB) May 18, 2010 -- Kantola Productions LLC has released ...
... effective way to convince young women to cut back on ... melanoma, the deadliest form of skin cancer, by 75 percent? ... "They,re not worried about skin cancer, but they are ... a professor of dermatology at Northwestern University Feinberg School of ...
... than thought, says a University of Florida researcher about a ... could lead to identifying those at risk for developmental disorders ... form of learning in sleeping newborns, a type of learning ... Byrd, a research affiliate in psychology at UF who collaborated ...
Cached Medicine News:Health News:Safe & Secure Online Pharmacy Viamedic.com; Reaches Milestone of 1.5 Million Orders Processed 2Health News:Chris Jay Hoofnagle to Deliver Keynote at the AdMonsters US Network Ad Ops Forum II, June 17, San Francisco 2Health News:Chris Jay Hoofnagle to Deliver Keynote at the AdMonsters US Network Ad Ops Forum II, June 17, San Francisco 3Health News:How Health Plans Can Turn Customer Touch Points into a Competitive Advantage – Whitepaper Release 2Health News:Kantola Productions Releases Workplace Violence Prevention Training Video 2Health News:Wrinkles are scarier than skin cancer for young tanners 2Health News:Wrinkles are scarier than skin cancer for young tanners 3Health News:Newborn infants learn while asleep; study may lead to later disability tests 2
... V is a low viscosity bone cement, ... vertebroplasty. The bone cement is injected into ... Osteopal V is used for the augmentation ... zirconium dioxide is included in the cement ...
Leadpoint Micro-Electrode Recording...
Based on the trusted Schaltenbrand-Wahren Atlas for Stereotaxy of the human brain, Atlasplan Software provides anatomical detail of the basal ganglia region of the brain and can help confirm target a...
Stereoplan, a three-dimensional software package for planning stereotactic procedures. Stereoplan provides diverse compatibility by supporting both the Radionics CRW frame and the Leksell G frame....
Medicine Products: